Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

Imagem de Miniatura
Arquivos
art_DALL'OGLIO_Alpha_Emitter_Radium_223_and_Survival_in_Metastatic_2013.PDF (1 MB)
Citações na Scopus
2596
Tipo de produção
article
Data de publicação
2013
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MASSACHUSETTS MEDICAL SOC
Autores
PARKER, C.
NILSSON, S.
HEINRICH, D.
HELLE, S. I.
O'SULLIVAN, J. M.
FOSSA, S. D.
CHODACKI, A.
WIECHNO, P.
LOGUE, J.
SEKE, M.
Citação
NEW ENGLAND JOURNAL OF MEDICINE, v.369, n.3, p.213-223, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases. Methods In our phase 3, randomized, double-blind, placebo-controlled study, we randomly assigned 921 patients who had received, were not eligible to receive, or declined docetaxel, in a 2:1 ratio, to receive six injections of radium-223 (at a dose of 50 kBq per kilogram of body weight intravenously) or matching placebo; one injection was administered every 4 weeks. In addition, all patients received the best standard of care. The primary end point was overall survival. The main secondary efficacy end points included time to the first symptomatic skeletal event and various biochemical end points. A prespecified interim analysis, conducted when 314 deaths had occurred, assessed the effect of radium-223 versus placebo on survival. An updated analysis, when 528 deaths had occurred, was performed before crossover from placebo to radium-223. Results At the interim analysis, which involved 809 patients, radium-223, as compared with placebo, significantly improved overall survival (median, 14.0 months vs. 11.2 months; hazard ratio, 0.70; 95% confidence interval [CI], 0.55 to 0.88; two-sided P=0.002). The updated analysis involving 921 patients confirmed the radium-223 survival benefit (median, 14.9 months vs. 11.3 months; hazard ratio, 0.70; 95% CI, 0.58 to 0.83; P<0.001). Assessments of all main secondary efficacy end points also showed a benefit of radium-233 as compared with placebo. Radium-223 was associated with low myelosuppression rates and fewer adverse events. Conclusions In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival. (Funded by Algeta and Bayer HealthCare Pharmaceuticals; ALSYMPCA ClinicalTrials.gov number, NCT00699751.)
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/1671
Referências
  1. Adami S, 1997, CANCER, V80, P1674, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1674::AID-CNCR18>3.0.CO;2-X
  2. Bruland OS, 2006, CLIN CANCER RES, V12, p6250S, DOI 10.1158/1078-0432.CCR-06-0841
  3. Cella D, 2009, VALUE HEALTH, V12, P124, DOI 10.1111/j.1524-4733.2008.00409.x
  4. de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X
  5. De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618
  6. Finlay Ilora G, 2005, Lancet Oncol, V6, P392, DOI 10.1016/S1470-2045(05)70206-0
  7. Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
  8. Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140-6736(10)62344-6
  9. Harris V, 2011, CLIN ONCOL-UK, V23, P706, DOI 10.1016/j.clon.2011.04.014
  10. Henriksen G, 2002, CANCER RES, V62, P3120
  11. Henriksen G, 2003, J NUCL MED, V44, P252
  12. Kerr C, 2002, LANCET ONCOL, V3, P453, DOI 10.1016/S1470-2045(02)00835-5
  13. LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502
  14. Lange PH, 1998, CANCER METAST REV, V17, P331, DOI 10.1023/A:1006106209527
  15. Lewington VJ, 2005, J NUCL MED, V46, p38S
  16. Li Yong, 2004, Expert Rev Anticancer Ther, V4, P459, DOI 10.1586/14737140.4.3.459
  17. Liepe K, 2009, CURR OPIN INVEST DR, V10, P1346
  18. Lipton A, 2010, SEMIN ONCOL, V37, pS15, DOI 10.1053/j.seminoncol.2010.10.002
  19. McDevitt MR, 1998, EUR J NUCL MED, V25, P1341, DOI 10.1007/s002590050306
  20. Nilsson S, 2007, LANCET ONCOL, V8, P587, DOI 10.1016/S1470-2045(07)70147-X
  21. Nilsson S, 2005, CLIN CANCER RES, V11, P4451, DOI 10.1158/1078-0432.CCR-04-2244
  22. Nilsson S, 2012, EUR J CANCER, V48, P678, DOI 10.1016/j.ejca.2011.12.023
  23. OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245
  24. OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
  25. Parker CC, 2013, EUR UROL, V63, P189, DOI 10.1016/j.eururo.2012.09.008
  26. Perlroth DJ, 2012, AM SOC CLIN ONC GEN
  27. Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
  28. Sartor O, 2011, CLIN GENITOURIN CANC, V9, P1, DOI 10.1016/j.clgc.2011.08.001
  29. Sartor O, 2011, ASIAN J ANDROL, V13, P366, DOI 10.1038/aja.2011.23
  30. Sartor O, 2011, ASIAN J ANDROL, V13, P783, DOI 10.1038/aja.2011.120
  31. Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506
  32. Silberstein EB, 2000, SEMIN RADIAT ONCOL, V10, P240, DOI 10.1053/srao.2000.6592
  33. Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/55
Artigos e Materiais de Revistas Científicas - ODS/03